| Autor: |
Takusagawa, Shin, Treijtel, Nicoline, Saito, Masako, Michon, Ingrid, Miyatake, Daisuke, Osaki, Fumio, Guro, Sayuri, Fadini, Tomasso, Sekino, Hisakuni, Aarden‐Bakker, Marlous, Kuroishi, Kentaro, Till, Jan Willem Olivier, Groenendaal‐van de Meent, Dorien, Vries, Michiel |
| Zdroj: |
Clinical Pharmacology in Drug Development; October 2024, Vol. 13 Issue: 10 p1130-1142, 13p |
| Abstrakt: |
ASP8302 is an orally administered positive allosteric modulator of the muscarinic M3receptor. Two Phase 1 studies were conducted, a first‐in‐human study in Europe and a Japanese phase 1 study. Both were randomized, participant‐ and investigator‐blinded, placebo‐controlled, single and multiple ascending oral doses, parallel group, clinical studies in healthy volunteers. Both studies evaluated safety and pharmacokinetics and also included salivary secretion and pupil diameter as pharmacodynamic assessments. There were no deaths, serious adverse events, or treatment‐emergent adverse events reported leading to study discontinuation. There were no clinically relevant findings in any of the laboratory, vital signs, electrocardiogram assessments, or photosensitivity testing following multiple administration of up to 150 mg or up to 140 mg once daily for 14 days in the European first‐in‐human and Japanese Phase 1 study, respectively. The pharmacokinetics of ASP8302 were approximately linear over the dose range studied. There was no evidence of drug accumulation upon repeated dosing. In both studies, ASP8302 showed a dose‐dependent pharmacodynamic effect on saliva production at doses from 100 mg onward, which was maintained during repeated dosing. No effect was observed on pupil diameter. These data supported progression of ASP8302 into Phase 2 clinical trials for further clinical development. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text